|
R&D Pipeline News Vol. 2, Issue 12: Inclu. Company profile Bayer Schering Pharma |
|
|
|
28 Mar 2006 |
 |
| |
Featured company profile after M&A: Bayer Schering Pharma
Special Pipelines
|
Vol. 2 Issue nº 12
March 27, 2006
|
 |
|
|
Featured company profile after M&A: Bayer Schering Pharma
|
1. Major Products
|
- Combined pharmaceutical product sales of € 9.3 bln
- Top selling biologics are Betaseron (Schering) and Kogenate (Bayer);
- Schering product focus on contraception and imaging;
- Bayer product focus on cardiovascular and infectious diseases
|
2. Contraception R&D
|
- Schering market leader in specialty field of contraception;
- R&D in advanced stages;
- Endometriosis as upside field
|
3. Oncology R&D
|
- Only R&D field with activities from both companies;
- Nearly no overlap in clinical stage projects;
- Well filled combined pipeline
|
4. Cardiovascular R&D
|
- Only Bayer active in cardiovascular research
- Gap in mid stage development pipeline
- Life cycle management activities for Kogenate and Trasylol
|
5. Others R&D
|
- Life cycle management projects for antibiotic and PDE-5 inhibitor;
- Stand-alone metabolic projects in diabetes and dyslipidemia;
- Up side indications for sargramostime, interferon, alemtuzumab;
- Cell therapy project in Parkinson's disease
|
|
|
Special Pipeline
|
1. Recombinant hemophilia A products
|
- Market conversion from purified to recombinant factor VIII products > 75 %;
- Further improvements by sucrose-free formulations and plasma and albumin free manufacturing process;
- Needle-free injection devices for more convenience
|
|
R&D Pipeline News
Get your Subscription Now
|
R&D Pipeline News is a premier information source about research and development (R&D) projects in the pipeline of the biopharmaceutical industry and is directed to all stakeholders in R&D . R&D Pipeline News covers all relevant treatment modalities, including. drugs, medical devices, biomaterials, combination products, cell therapy and drug delivery products.
Read more about R&D Pipeline NewsOrder Now
 
|
|
|
|
|
|
|
|
| |
|
